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Abst rac t  
Between April 9 and May 5 2000, an outbreak of fatal cardiotoxicity occurred in Nepal amongst visceral 
leishmaniasis patients treated with a recently introduced batch of generic sodium stibogiuconate (SSG) 
from GL Pharmaceuticals, Calcutta, India. Eight (36%) of 23 patients treated with this batch died, and 
in 5 (23%) death was attributed to the cardiotoxieity of the drug. This contrasts with the low total death 
rate (3.2%) and death rate due to cardiotoxicity (0.8%) observed among 252 patients treated between 
August 1999 and December 2001 with generic SSG from Albert David Ltd, Calcutta, India. These data 
show that every batch of generic SSG should be subject o rigorous quality control prior to use. 
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I n t roduct ion  
Visceral eishmaniasis (VL: kala-azar) remains highly 
endemic in many poor rural regions of India and Nepal. 
First-line treatment for visceral eishmaniasis n Nepal 
is sodium stibogluconate (SSG) 20 mg/kg/d i.m. for 
30 d, as recommended by WHO. In Nepal, the Epi- 
demiology and Disease Control Division (EDCD), 
Ministry of Health, distributes SSG to all hospitals 
managing VL patients. 
As a high level of resistance to antimonials is cur- 
rently being observed in the neighbouring Indian state 
of Bihar (Sundar et al., 2000), we monitored the 
efficacy of SSG therapy at the B. P. Koirala Institute of 
Health Sciences (BPKIHS), a tertiary care centre lo- 
cated in Dharan, Nepal, from August 1999. For several 
years, the source of SSG was an Indian generic supplier 
(Albert David Ltd, Calcutta, India), and this drug, also 
called sodium antimony gluconate (SAG), has been 
used at BPKIHS without significant problems of toxi- 
city or lack of efficacy. From 2 April 2000 onwards, the 
EDCD central pharmacy supplied generic SSG from 
another Indian manufacturer, GL Pharmaceuticals, 
Calcutta, India. At the beginning of May 2000, physi- 
cians at BPKIHS were alerted by an increase in the 
case-fatality rate in VL patients. The recently intro- 
duced brand of SSG was highly suspected as the 
potential cause of the increased mortality and it was 
discontinued on 7 May 2000. From that date onwards, 
VL patients were again treated with generic SSG man- 
ufactured by Albert David Ltd. We report the investi- 
gation of this increased mortality. 
Methods  
We carefully reviewed the files of all the 23 patients 
treated with SSG from GL Pharmaceuticals. Moreover, 
we also analysed the outcome for VL admitted to 
BPKIHS since August 1999, and reviewed the causes 
of death reported. 
Resu l ts  
Between August 1999 and December 2001, 
BPKIHS admitted 275 patients with parasitologically 
confirmed VL for treatment with SSG. All patients 
were admitted for at least 1 week and 42% were 
admitted for the full duration of treatment. Ninety-five 
percent of patients had a check-up performed at 1 
month after completion of the drug course. Of the 23 
VL patients who received 5 or more doses of SSG from 
GL Pharmaceuticals, 8 (36.4%) died, including 5 
(22.7%) with either ECG-proven (ventricular tachycar- 
dia or fibrillation) or high clinical suspicion (cardiac 
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arrest) of cardiotoxicity. These 5 patients received a 
median of 27 doses of SSG (range 8-34). Of the other 
3 patients (13.6%) who died, the cause of death was 
bacterial meningitis in 1 and sepsis with bleeding in the 
other 2. In contrast, during a 2.5-year period, of the 
252 patients treated with SSG from Albert David Ltd, 
only 8 (3.2%) had a fatal outcome (Figure). Of the 8 
deaths, 2 (0.8%) were attributed to cardiotoxicity. The 
relative risk of death in patients treated with SSG from 
GL Pharmaceuticals compared with patients treated 
with SSG from Albert David Ltd was 11.0 (95% CI 
4.5-26.5). 
Discuss ion  
The risk of fatal complications in patients treated 
with SSG for leishmaniasis should not be underesti- 
mated. Whereas SSG is considered safe at the WHO 
recommended dosages by Berman (1988), this mainly 
refers to patients treated for cutaneous or mucocuta- 
neous leishmaniasis. In Indian VL patients, death due 
to cardiotoxicity was recently reported in 5.9% of 
patients (Sundar et al., 2000). Visceral leishmaniasis 
patients frequently present with an altered general con- 
dition including malnutrition and superimposed bac- 
terial infections. Cardiotoxicity is more likely in these 
patients, possibly because of concomitant electrolyte 
disturbances, micronutrient or vitamin deficiencies. An 
outbreak of cardiotoxicity has already been reported in 
India where 3 of 8 patients treated with genetic SSG 
died due to an excessively high osmolarity (Sundar et 
al., 1998). Unfortunately, analysis of the content of the 
suspected batch of SSG from GL Pharmaceuticals u ed 
at BPKIHS could not be performed because all remain- 
ing vials were rapidly called back and estroyed by the 
EDCD in Kathmandu to prevent its further use in the 
endemic region. The increased mortality observed at 
BPKIHS in April and May 2000 was also observed 
concomitantly in several other hospitals in Nepal. In- 
terestingly, a similar problem involving the same SSG 
manufacturer seemed to have occurred also in India 
during the same period as the 10 June 2000 edition of 
an Indian daily newspaper 'The Statesman' published a
front-page article entitled 'The return of the killer injec- 
tion' (Chakraborty, 2000). 
The production of SSG is a difficult process and a 
significant proportion produced has commonly to be 
discarded because it is of insufficient quality. This 
might explain partly the high cost of branded antimo- 
nials (US$150-200 per patient for a full drug course), 
and gives food for thought as to the origin of toxic 
generic batches. Genetic SSG was advocated as a solu- 
tion to the drug access problem in developing coun- 
tries, because of its better affordability (US$13-16 per 
patient per course). In that regard, recent studies com- 
paring the generic SSG (SAG) from Albert David Ltd 
and the branded SSG (Pentostam ® from Glaxo-Well- 
come, London, UK) performed in Kenya, Sudan, and 
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Figure. Number of patients, total deaths, and deaths due to cardiotoxicity amongst visceral eishmaniasis patients treated with 
generic sodium stibogluconate at the B. P. Koirala Institute of Health Sciences, Dharan, Nepal from August 1999 to December 
2001. 
Ethiopia showed equivalent efficacy and toxicity (Vee- 
ken et al., 2000; Moore et al., 2001; Ritmeijer et al., 
2001). The use and distribution of cheaper generic 
antimonials should thus be strongly promoted but this 
should be done with appropriate assurance of safety 
and efficacy. We believe that generic SSG should be 
widely used in VL-endemic countries but that rigorous 
quality controls should be performed on every batch to 
prevent outbreaks of fatal complications as reported 
here. For example, independent quality control of every 
single batch of SSG from Albert David Ltd is currently 
being implemented by the International Dispensary 
Association, Amsterdam, The Netherlands before dis- 
tribution to East African countries. Also, the use of 
lower total doses of SSG by using combination thera- 
pies (e.g. SSG with paromomycin) might efficiently 
decrease its dose-dependent cardiotoxicity. 
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